Syneos Health US, Inc., a leading biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has quickly established itself in the clinical research and commercialisation sectors. Specialising in integrated biopharmaceutical solutions, Syneos Health offers a unique combination of clinical development and commercial services, enabling clients to accelerate the delivery of innovative therapies to market. Their commitment to a patient-centric approach and advanced technology sets them apart in a competitive landscape. With a strong market position, Syneos Health has achieved notable milestones, including recognition for its innovative strategies in clinical trial management and patient engagement. The company continues to drive advancements in the healthcare industry, making significant contributions to the success of its partners.
How does Syneos Health US, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Syneos Health US, Inc.'s score of 70 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Syneos Health US, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Syneos Health, Inc., which may influence its climate commitments and initiatives. As of now, there are no documented reduction targets or significant climate pledges reported for Syneos Health US, Inc. However, it is important to note that the company inherits its climate initiatives from its parent organisation, Syneos Health, Inc. This includes participation in various climate-related initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), although specific targets or achievements have not been disclosed. In the absence of specific emissions data, it is clear that Syneos Health US, Inc. is part of a broader corporate commitment to addressing climate change through inherited initiatives from its parent company. Further details on their climate strategy and performance may be available through Syneos Health, Inc.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 16,298,000 | 00,000,000 |
| Scope 2 | 9,704,000 | 0,000,000 |
| Scope 3 | 261,804,000 | 000,000,000 |
Syneos Health US, Inc.'s Scope 3 emissions, which decreased by 14% last year and decreased by approximately 14% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Syneos Health US, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.